Middle East respiratory syndrome–related coronavirus

CEPI Boosts ‘Coronavirus X’ Vaccine Search With Expanded VBI Vaccines Deal

Retrieved on: 
Tuesday, December 6, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Other Science, Research, Infectious Diseases, Science, Clinical Trials, Nipah virus, Interim, Coalition for Epidemic Preparedness Innovations, Infection, Disease, Government of Canada, COVID-19, G7, Risk, Chikungunya, Cytomegalovirus, Virus, National Research Council, Partnership, Coronavirus, Epidemic, Multimedia, Vaccine, COVID-19 vaccine, Severe acute respiratory syndrome coronavirus 2, Glioblastoma, Middle East respiratory syndrome–related coronavirus, Omicron, Hepatitis B, Lassa mammarenavirus, Science, VLP, CEPI, CMV, Severe acute respiratory syndrome coronavirus, Immunity, Nature, COVAX, Immune system, NRC, Rift Valley fever, Pandemic, Research, Annual report, Human coronavirus 229E, Public sector, VBI, News, Safety, G20, GBM, Coalition, Animal, Pharmaceutical industry

The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.

Key Points: 
  • The Coalition for Epidemic Preparedness Innovations (CEPI) is expanding its world-leading portfolio of potential variant-proof coronavirus vaccines in a deal with VBI Vaccines Inc. (Nasdaq: VBIV) to advance the development of multivalent coronavirus shots that could be deployed against COVID-19 as well as a future Coronavirus X.
  • Application of this funding will now be directed into the broader development of the VBI-2900 coronavirus vaccine program to explore the Coronavirus X potential of VBIs technology.
  • We have long recognized the public health value that multivalent vaccines capable of anticipating new variants and coronavirus strains could provide.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

Retrieved on: 
Monday, November 28, 2022
Aikido, ASPI, University, University of Maryland, College Park, Pancreatic cancer, Biotechnology, Middle East respiratory syndrome–related coronavirus, IPO, University of Texas at Austin, Risk, Memory, Therapy, Prostate cancer, ASP, Coronavirus, Isotope, Security (finance), Ebolavirus

NEW YORK, Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI"). ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.

Key Points: 
  • Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI
    NEW YORK, Nov. 28, 2022 /PRNewswire/ --AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the successful initial public offering ("IPO") of ASP Isotopes ("ASPI").
  • ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses.
  • Mr. Anthony Hayes, CEO of AIkido stated, "As a shareholder of ASP Isotopes, we want to congratulate the company and their CEO, Paul Mann on successfully listing on NASDAQ.
  • We congratulate Paul and his team for getting this public offering over the line.

AIkido Share Repurchase Continues

Retrieved on: 
Thursday, October 6, 2022
Aikido, Pancreatic cancer, Therapy, Middle East respiratory syndrome–related coronavirus, SEC, Securities Exchange Act of 1934, Biotechnology, Special-purpose acquisition company, Program, University of Maryland, College Park, Coronavirus, Nasdaq, University, Company, Share repurchase, Board, Prostate cancer, Board of directors, University of Texas at Austin, Risk, Security (finance), Ebolavirus

NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 5, 2022, the Company purchased 10,500 shares of common stock at $7.0679 per share.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.
  • Certain statements in this press release constitute "forward-looking statements" within the meaning of the federal securities laws.

AIkido Purchases More Shares

Retrieved on: 
Wednesday, October 5, 2022
Aikido, Pancreatic cancer, Therapy, Middle East respiratory syndrome–related coronavirus, SEC, Securities Exchange Act of 1934, NASDAQ, Biotechnology, Special-purpose acquisition company, Program, University of Maryland, College Park, Coronavirus, University, Company, Share repurchase, Board, CEO, Prostate cancer, Board of directors, University of Texas at Austin, Risk, Security (finance), Ebolavirus

NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 4, 2022, the Company purchased 38,035 shares of common stock at $6.99 per share.
  • Anthony Hayes, CEO of AIkido stated, "We believe the Company stock continues to be undervalued and we are using this opportunity to enhance shareholder value by reducing the amount of stock that is outstanding."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

Share Repurchase Program Continues

Retrieved on: 
Tuesday, October 4, 2022
Securities Exchange Act of 1934, Genta (company), Aikido, SEC, University, Risk, Nasdaq, Middle East respiratory syndrome–related coronavirus, University of Texas at Austin, Share repurchase, Pancreatic cancer, Coronavirus, Program, Biotechnology, University of Maryland, College Park, Board of directors, Prostate cancer, Board, Therapy, Company, Security (finance), Ebolavirus

NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on October 3, 2022, the Company purchased 45,000 shares of common stock at $6.98 per share.
  • The timing, number of shares repurchased, and prices paid for the stock under this program will depend on general business and market conditions as well as corporate and regulatory limitations, including blackout period restrictions.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

Middle East Respiratory Syndrome (MERS) Drug Pipeline Market Insights Report 2022: 12+ Companies and 12+ Pipeline Drugs in the Pipeline Landscape - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Health, Other Health, Vaccine, Vaccitech, News, Middle East respiratory syndrome coronavirus outbreak, Technology, ChAdOx1, Disease, Severe acute respiratory syndrome coronavirus 2, Clinical trial, Middle East respiratory syndrome–related coronavirus, II, NDA, MERS, Antibody, Inovio Pharmaceuticals, Infection, Coronavirus, Discovery, Acquisition, Human coronavirus 229E, DNA, Therapy, Pharmaceutical industry

The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.

Key Points: 
  • The "Middle East Respiratory Syndrome - Pipeline Insight, 2022," report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Middle East Respiratory Syndrome pipeline landscape.
  • The assessment part of the report embraces, in depth Middle East Respiratory Syndrome commercial assessment and clinical assessment of the pipeline products under development.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Middle East Respiratory Syndrome R&D.
  • The companies which have their Middle East Respiratory Syndrome drug candidates in the most advanced stage, i.e.

Synairgen announces positive data from the US NIH-led ACTIV-2 Phase 2 trial for SNG001 in home-based participants with COVID-19

Retrieved on: 
Tuesday, October 4, 2022
Health, Other Health, COVID-19, Clinical Trials, Pharmaceutical, Biotechnology, COVID, Interferon, RSV, Adult, Degenerative disease, Protocol, Research, Delta, Severe acute respiratory syndrome coronavirus 2, Drug discovery, Food, CEO, Arm, Middle East respiratory syndrome–related coronavirus, Virus, NIH, Patient, FDA, LSE, ACTG, Phase II, COVID-19, Viral pneumonia, AIM, University of North Carolina, Urinary tract infection, Partnership, Safety, University of Southampton, Inhalation, Alpha, National, ACTIV, Travel, NIAID, University, US Foods, UNC, AIDS Clinical Trials Group, Company, Virology, Rhinovirus, Pharmaceutical industry, Vaccine, Omicron, Vaccine, EU, Synairgen

There were no statistically significant differences between SNG001 and placebo with respect to the primary outcomes of safety (SNG001 was well-tolerated), symptom resolution, or virology.

Key Points: 
  • There were no statistically significant differences between SNG001 and placebo with respect to the primary outcomes of safety (SNG001 was well-tolerated), symptom resolution, or virology.
  • Based on the study results, the Independent Data Safety Monitoring Board for ACTIV-2 recommended SNG001 advance from Phase 2 into Phase 3 in the ACTIV-2 trial in October 2021.
  • We will now begin to evaluate the full data set and factor these findings into our development plans.
  • 2 Synairgen conducted a trial of SNG001 in high-risk, home-based COVID-19 patients (SG016) in which fewer patients treated with SNG001 were hospitalised (0/56) compared to placebo (2/58).

AIkido Pharma Continues Share Repurchase Program

Retrieved on: 
Monday, October 3, 2022
Securities Exchange Act of 1934, Special-purpose acquisition company, Aikido, SEC, University, Risk, Nasdaq, CEO, Middle East respiratory syndrome–related coronavirus, University of Texas at Austin, Share repurchase, Pancreatic cancer, Coronavirus, Program, Biotechnology, University of Maryland, College Park, Board of directors, Prostate cancer, Board, Therapy, Company, Online gambling, Security (finance), Ebolavirus

NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.

Key Points: 
  • NEW YORK, Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program") authorized by the Company's Board of Directors on January 21, 2022.
  • The Company reported that on September 30, 2022, the Company purchased 41,096 shares of common stock at $ 7.1034 per share.
  • Anthony Hayes, CEO of Aikido stated, "The Company's stock price is still below our book value, so we are continuing to allocate capital under our repurchase plan.
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anticancer and antiviral therapeutics.

VBI Vaccines Announces Initiation of Phase 1 Study of Multivalent Coronavirus Vaccine Candidate, VBI-2901

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, FDA, Other Health, Health, Pharmaceutical, Oncology, Research, Infectious Diseases, Science, COVID-19, Clinical Trials, Government of Canada, Middle East respiratory syndrome–related coronavirus, Trial of the century, Safety, COVID-19, Virus, Severe acute respiratory syndrome coronavirus 2, Nature, VLP, Company, GBM, Private Securities Litigation Reform Act, Hepatitis B, Industry, Mouse, ISED, Glioblastoma, Coalition for Epidemic Preparedness Innovations, MERS, Epidemic, NRC, Health Canada, CEO, SARS, Technology, Vaccine, Annual report, Nasdaq, Omicron, Coronavirus, VBI, Government, Economic development, Infection, Research, Cytomegalovirus, National Research Council, SEC, Immune system, Disease, CMV, Coalition, CEPI, Pharmaceutical industry, Science, Lambda

As we work to develop a vaccine capable of providing broad protection against known, emerging, and as-yet-unknown COVID-19 and coronavirus strains, we believe this study initiation is a meaningful step toward that goal.

Key Points: 
  • As we work to develop a vaccine capable of providing broad protection against known, emerging, and as-yet-unknown COVID-19 and coronavirus strains, we believe this study initiation is a meaningful step toward that goal.
  • Each participant must have received their previous dose of a licensed COVID-19 vaccine at least six months prior to study enrollment.
  • VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease.
  • VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer

Retrieved on: 
Friday, September 9, 2022
University, NASDAQ, Biotechnology, Industry, Prostate cancer, Pancreatic cancer, FINRA, UHNW, Technology, Risk, Science and technology in Asia, SEC, Company, Therapy, Aikido, Intention, Coronavirus, Middle East respiratory syndrome–related coronavirus, Acquisition, Security (finance), Financial services, Ebolavirus

NEW YORK, Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an exclusive agreement for the acquisition of a broker-dealer firm. This is Dominari's first acquisition since launching in June. Details of the proposed purchase can be found in the 8K on file with the SEC.

Key Points: 
  • Dominari Financial was formed with the intention of acquiring revenue generating assets in the fintech and financial services industry.
  • This transformative purchase not only accelerates our timetable, but also gives us the organizational infrastructure and technology needed to scale Dominari into a financial services powerhouse," said Carlos Aldavero, President of Dominari.
  • "The board fully supports the diversification strategy of which Dominari Financial is the centerpiece," added Wool.
  • "Once approved by FINRA, this acquisition will catapult Dominari forward and lays the groundwork for future acquisitions.